Caprihans India Limited Allots Equity Shares Upon Warrant Conversion
Caprihans India Limited announced on March 25, 2026, the allotment of 330,000 equity shares to Bilcare Limited, the company’s promoter, through the conversion of an equal number of warrants. This conversion follows the receipt of the remaining 75% of the warrant price, totaling Rs. 495 million.The equity shares are being issued at a face value of Rs. 10 per share, with a premium of Rs. 190 per share, resulting in an aggregate value of Rs. 660 million. The allotment was approved via resolution by circulation in accordance with the Companies Act, 2013.
As a result of this allotment, the company's paid-up equity share capital has increased from Rs. 1558.40 million to Rs. 1591.40 million.
Bilcare Limited’s post-issue equity holding increased to 94,78,325 shares, representing 59.56% of the company’s equity. Prior to the conversion, Bilcare held 91,48,325 shares, or 58.70% of the company’s equity.
The allotment is related to warrants initially issued to Bilcare Limited on a preferential basis with shareholder approval obtained on November 8, 2024. Previous allotments of equity shares related to warrant conversions occurred on January 10, 2025, January 17, 2025, January 20, 2025, March 20, 2026, March 23, 2026, and March 24, 2026.
| Sr. No. | Particulars | Details | Details | Details | Details |
|---|---|---|---|---|---|
| 3. | Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately) | Equity Shares: 3,30,000 | Equity Shares: 3,30,000 | Equity Shares: 3,30,000 | Equity Shares: 3,30,000 |
| b. | Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors | Bilcare Limited | 91,48,325 (58.70%) | 3,30,000 | 94,78,325 (59.56%) |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.